|
Number
|
129
|
20
|
49
|
60
|
|
Age (years; median, range)
|
72 (47–86)
|
76 (53–86)
|
74 (50–83)
|
69 (47–83)
|
|
Gleason Score [pts]
|
|
6
|
11 (8.5%)
|
3 (15%)
|
7 (14.3%)
|
1 (1.7%)
|
|
7a
|
27 (20.9%)
|
3 (15%)
|
19 (38.8%)
|
5 (8.3%)
|
|
7b
|
37 (28.7%)
|
6 (30%)
|
11 (22.4%)
|
20 (33.3%)
|
|
8
|
18 (14%)
|
3 (15%)
|
7 (14.3%)
|
8 (13.3%)
|
|
9
|
34 (26.4%)
|
5 (25%)
|
5 (10.2%)
|
24 (40.0%)
|
|
10
|
2 (1.6%)
|
–
|
–
|
2 (3.3%)
|
|
Risk group (D’Amico) [pts]
|
|
low
|
5 (3.9%)
|
1 (5.0%)
|
3 (6.1%)
|
1 (1.7%)
|
|
intermediate
|
21 (16.3%)
|
2 (10.0%)
|
13 (26.5%)
|
6 (10.0%)
|
|
high
|
103 (79.8%)
|
17 (85%)
|
33 (67.3%)
|
53 (88.3%)
|
|
PSMA PET positive [pts]
|
92 (71.3%)
|
20 (100%)
|
27 (55.1%)
|
45 (75%)
|
|
PSA PRE-PSMA PET [ng/ml] (median/mean, range)
|
0.86/6.04 (0.13–150.00)
|
12.4/27.28 (0.14–150.0)
|
0.49/1.00 (0.15–6.24)
|
0.99/3.08 (0.13–39.2)
|
|
PSA doubling time
|
|
≤ 10 months
|
81 (74.3%)
|
–
|
21 (42.9%)
|
60 (100%)
|
|
> 10 months
|
28 (25.7%)
|
–
|
28 (57.1%)
|
–
|
|
ADT at time of PET [pts]
|
14 (10.9%)
|
2 (10%)
|
4 (8.2%)
|
8 (13.3%)
|
|
Activity of 68Ga-PSMA-HBED-CC [MBq] (mean, range)
|
190.43 (87–293)
|
197.50 (100–293)
|
192.07 (94–293)
|
186.85 (87–286)
|
